ADAG

Adagene Inc. (NASDAQ:ADAG) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Suzhou, China. The company went public on February 9, 2021, and focuses on developing innovative monoclonal antibody therapies for cancer treatment. Adagene specializes in creating next-generation antibody drugs using proprietary platforms to address limitations of existing cancer immunotherapies. The company operates primarily in the oncology space, developing treatments for both solid tumors and blood cancers.